It has recently been suggested that a substitution of glutamlne for arginlne at residue 3500 of apolipoprotein (apo) B-100 causes familial defective apo B-100 (FDB), an autosomal, dominantly Inherited disorder, which leads to Increased serum cholesterol levels. From a sample of 243 patients from Munich with type Ma hyperllpoprotelnemia (HL), we have Identified eight individuals with the apo B-100 arglnlne ( j 600) -»glutamine mutation. In a group of 57 subjects with defective low density llpoproteln receptor (LOLR), no mutant apo B alleles were detected. The frequency of FDB In patients with type Ha HL was estimated to be 3%. In the kindreds of three of the probands, 10 additional carriers of the apo B mutation were Identified. Clinical and biochemical data reveal a striking similarity between patients with FDB and those with a defect in the LDLR gene. Our data support previous findings that FDB Is a serious disorder causing premature atherosclerosis.
I
t is well established that hypercholesterolemia is one of the major causes of premature coronary artery disease (CAD). 1 Brown, Goldstein, and co-workers 2 have
shown that different genetic defects in the low density lipoprotein receptor (LDLR) that normally controls the removal of LDL from plasma lead to the disorder, familial hypercholesterolemia (FH), which is clinically characterized by increased serum LDL cholesterol levels, tendon xanthomata, and increased risk of myocardial infarction. However, FH accounts for only a small fraction of the individuals with high LDL cholesterol levels in the population, and most individuals with elevated LDL cholesterol appear to have normal LDLR activity. Turnover studies of autologous and normal homologous LDL performed in patients with primary hypercholesterolemia have shown reduced fractional catabolic clearance in some cases. 3 Binding studies with monoclonal antibodies against various epitopes of apo B-100 have revealed low affinity for the LDLR due to a defect in the binding site. 46 Further studies 6 at the DNA level identified a single-nucleotide substitution from G to A at nucleotide 10 699, which results in a glutamine for arginine substitution at residue 3500. To date, all individuals with this mutant allele have been hypercholesterolemic subjects. Studies of kindreds of these patients indicate that the defect is inherited in an autosomal dominant fashion. Cosegregation of the G to A mutation with defective LDL was shown in family studies, and, taken together, this indicates that the mutation is the underlying
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Received November 8, 1989 ; revision accepted February 12, 1990. cause of this disorder, which has been designated familial defective apo B-100 (FDB). In a recent study, 7 10 unrelated individuals with FDB from the U.K. and Scandinavia have been identified. By contrast with the previous report, 5 many of these probands had severe hypercholesterolemia and CAD and a primary diagnosis of FH. Therefore, in the present investigation, we screened German patients with hypercholesterolemia above the 95th percentile of the normal distribution for the presence of the apo B-100 argininepeoo)->glutamine mutation. The clinical data of individuals who are hypercholesterolemic due to defects in the LDLR and individuals who have FDB were compared.
Methods Subjects
A total of 300 hypercholesterolemic subjects were investigated for the presence of the apo B-100 argininepjiooj-^glutamine mutation. All individuals were recruited from a single lipid clinic at the Medizinische Poliklinik in Munich and were divided into the following subgroups (Table 1) . Group 1 consisted of 57 subjects who were previously diagnosed with a defective LDLR by either fibroblast tissue culture biochemistry 8 or linkage analysis by using restriction fragment length polymorphisms (RFLPs) of the LDLR gene as described before. 9 Group 2 consisted of 243 subjects with primary type lla hypertipoproteinemia (HL). These persons had total cholesterol levels above the 95th percentile (236 to 293 mg/dl); were 20 to 60 years old, had triglyceride levels below the 95th percentile (188 to 237 mg/dl), and were in the Munich population. 10 Individuals from Group 2 were a representative sample of type lla patients ascertained from all cases of hyperlipidemia referred to our lipid clinic since 1985. Individuals from Group 1 had been sampled since 1978 from an area of south Germany. Blood samples were taken 12 hours after the last meal. Cholesterol levels were determined after a period of at least 6 weeks without treatment or when the patients came to the lipid clinic for the first time and before therapy. Upoprotein levels were determined by preparative uttracentrifugation according to the method of Havel et al. 11 Blood cells were stored at -20°C for later DNA analysis.
Blood samples were taken for routine diagnosis of hypercholesterolemia. All investigations were made on cells taken from these samples. Patients were informed and consented to our studies according to the requirements of German law.
OAM Analysis
Total genomic DNA was extracted from white blood cells by using a Triton X-100 lysis method. The polymerase chain reaction (PCR) was used to amplify a 766 base pair region of the apo B gene spanning the mutation at position 10 699 in exon 26. 12 DNA was amplified by using the Cambio Intelligent Heating Block (Cambio, Cambridge, U.K.). Thermus aquatlcus DNA polymerase I was obtained from Perkin-Elmer (Langen, F.R.G.). Oligonucleotides were synthesized on a Pharmacia Gene Assembler (Pharmacia, Uppsala, Sweden). Amplified DNA was transferred to nylon membranes (Amersham, Braunschweig, F.R.G.) by using a slot blotting apparatus (Schleicher und Schuell, Dassel, F.R.G.), and DNA was fixed to the membranes by ultraviolet lighting. To detect the presence of the G to A mutation, filters were hybridized with allele-specific oligonucleotides (ASO) for 1 hour at 37°C in 5x sodium-sodium phosphate ethyienediamenetetraacetate (SSPE) (0.15 M NaCI, 10 mM NaH 2 PO 4 , 1 mM ethylenediaminetetraacetate [EDTA], pH 7.4), 5 x Denhardts solution, and 0.5% sodium dodecyl sulfate (SDS). ASOs were end-labeled with T4 polynucleotide kinase (Amersham) and T-32 ? adenoslne triphosphate (ATP) (Amersham). After hybridization, the filters were finally washed for 10 minutes at 4O°C in 5x SSPE and 0.1% SDS and were exposed to x-ray films (Kodak X-Omat AR) for 24 hours at -70°C.
In Figure 1 , the sequences of the PCR primers (PCO1 and PCO2) and the ASOs (ASO1 and ASO2) are shown. The two PCR primers are 30 and 29 bases long and span the site of the G to A mutation at nucleotide 10 699. The two ASO probes are 13 bases long and span the site of the mutation. ASO1 identifies the normal apo B allele, ASO2, the mutant allele. 
Results
A total of 300 unrelated hypercholesterolemic subjects were screened for the apo B-100 argininepsoo^gluta-mine mutation. In 57 individuals (Group 1), diagnosis of heterozygous FH due to a defective LDLR was made by using linkage analysis with RFLPs in the LDLR gene or by fibroblast tissue culture studies as described earlier. 89 As expected, no mutant apo B allele was detected in the FH group with defective LDLR. In 243 subjects with type lla HL, eight individuals with the G to A mutation at nucleotide 10 699 of the apo B gene were identified ( Table 1) . The frequency of the apo B-100 argininepsooi-^glutamine mutation was, therefore, 2.7% in the type lla HL group as a whole or 3.3% in the group in which patients with a known defect in the LDLR gene were excluded.
Relatives of three individuals with FDB were available for family studies. Within these families, we identified 10 additional subjects with the arginine ( 3 S oo)-> glutamine mutation, all of whom were hypercholesterolemic. Table 2 summarizes the clinical characteristics of the 18 individuals with the argininepsoo)-*9lutamine mutation. With the exception of one subject with type lib HL, all had marked type lla HL In 12 individuals, clinical data were available. Arcus lipoides was present in 40% of the individuals, and xanthomas in the Achilles tendons or the extensor tendons of the hand were present in 30%. Atherosclerotic plaques in the carotid arteries were detected in 60% by means of duplex scan. In two subjects, clinically relevant CAD was present before the age of 60. In 11 individuals, a defect in the LDLR was excluded by tissue culture biochemistry or linkage analysis in family studies. Figure 2 shows the pedigree of family 3198 with FDB. We identified the mutation in all hypercholesterolemic family members, while in normolipidemic individuals, we found only normal alleles. In all three families, there was no overlap of cholesterol levels between subjects with the argininepBog-^glutamlne mutation and normal subjects (Figure 3) . Table 3 compares lipid and lipoprotein levels in FH individuals with a defective LDLR, those individuals with apo B-100 argininepsog-^glutamine mutation, and the hypercholesterolemic individuals with neither defect. There was no significant difference in age, total cholesterol, or LDL cholesterol between men and women within the various groups, but triglyceride and high density lipoprotein (HDL) cholesterol levels showed significant gender-associated differences within each group (p<0.05). Individuals with defective LDLR (homozygous FH individuals excluded) had significantly higher total cholesterol and LDL cholesterol levels (p<0.0001) than those in the other groups. However, there was no significant difference in lipoprotein level between individuals with FDB and patients with type Ha of unknown etiology. Figure 4 plots the age-dependent total serum cholesterol levels for heterozygous FH individuals and FDB individuals.
Discussion
Mutations in the LDLR gene have been shown to cause FH, a genetically transmitted disorder, which leads to elevated serum LDL cholesterol levels, tendon xanthomatas, and premature CAD. Studies at the DNA level have greatly helped our understanding of the structure and function relationship of this protein and have identified this gene as important in lipid metabolism. However, because defects in this gene are relatively rare, attention has been focused on other possible genetic causes of hypercholesterolemia.
Recently, it was postulated that a G to A mutation in the apo B gene creates a substitution of glutamine for arginine in residue 3500 and results in the dominantly inherited genetic disorder, FDB. We have identified the apo B-100 argininepsoo^glutamine mutation in eight unrelated hypercholesterolemic individuals and thus classified about 3% of hypercholesterolemic individuals in our sample as heterozygous FDB patients. The apo B-100 argininepsooj-^glutamine mutation was not detected in normocholesterolemic relatives nor in any of these patients classified previously by cellular or genetic studies as having defects in the LDLR gene. Assuming a frequency of type Ha hyperlipidemia of five in 100 in the Munich population 10 and a general frequency of FH of one in 500, 13 an estimate of the frequency of the apo B-100 argininepsoq-^glutamine mutation in the general population is 3% x (5/100-1/500)» 1/700 and is thus Figure 2 and Table 2 . . I f * * * , * .
• FDB was first observed in individuals with moderate hypercholesterolemia. 5 However, as in the FDB patients reported in the U.K. and Scandinavian studies, 7 in the patients identified here, cholesterol levels were markedly elevated and were comparable to those in FH patients. Although the mean cholesterol levels in the FDB patients we studied is less than the level in patients with a defective LDLR, the range of levels in both groups overlaps. The frequency of clinical signs, as well as xanthomas, arcus lipoides, and premature atherosclerosis, exhibited no significant difference between these two disorders. Our findings thus suggest that clinical findings and family history of premature CAD are no longer appropriate to diagnose a defect in the LDLR gene. It is possible that these two distinct genetic disorders respond differently to various lipid-lowering drugs. Drugs that increase the number of LDL receptors on the cell surface may, therefore, be of limited value in patients with FDB. If so, it is important to distinguish genetic defects that lead to phenotypic, familially transmitted hyperchdesterolemia
